Chuvash polycythemia (CP) is a rare form of congenital polycythemia caused by mutations in
the VHL gene. Currently, there are no therapies that have proven effective for CP. Recent
studies have demonstrated that VHL (von Hippel-Lindau tumor suppressor) regulates the
activity of JAK2 (Janus kinase 2). In mouse models, inhibition of JAK2 reverses the CP
phenotype. Therefore, the investigators hypothesize that JAK2 inhibition may have significant
clinical benefits for CP patients.
We will connect you to the doctor responsible for this trial and help you get more information.
Locations near you
Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Full eligibility criteria for NCT01730755
Ages eligible for Study
Genders eligible for Study
Accepts Healthy Volunteers
Diagnosis of Chuvash polycythemia
Unable to comprehend or unwilling to sign an informed consent form.
All locations for NCT01730755
United States (1)
Washington University School of Medicine
Saint Louis, Missouri, United States, 63110
View full eligibility
Tris trial is registered with FDA with number: NCT01730755. The sponsor of the trial is Washington University School of Medicine and it is looking for 0 volunteers for the current phase. Official trial title: Ruxolitinib for Chuvash Polycythemia
Thank you for applying!
We'll contact you soon with more information.
FindMeCure is constantly improving its search. Take part in it and help millions by filling our patients' survey!